Although targeting the NKG2D ligand had the potential to induce on-target–off-tumor toxicity, no side effects were observed in mice exhibiting stable body weight, normal liver function and peripheral blood counts following administration of the CARs. This evidence concerns the gene KLRK1 and neoplasm.